Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing
Michelle M. Pham, Anthony T. Podany, Noluthando Mwelase, Khuanchai Supparatpinyo, Lerato Mohapi, Amita Gupta, Wadzanai Samaneka, Ayotunde Omoz-Oarhe, et al. (13 authors)
Antimicrobial Agents and Chemotherapy · 2022-08
Abstract
The Brief Rifapentine–Isoniazid Efficacy for TB Prevention/A5279 trial demonstrated a 1-month daily regimen of rifapentine and isoniazid was noninferior to 9 months of isoniazid alone for preventing TB in persons living with HIV (PLWH). Our objective was to evaluate rifapentine pharmacokinetics in trial participants receiving antiretroviral therapy (ART) and perform simulations to compare weight-based rifapentine dosing with a standard, fixed dose.
MeSH terms
- Rifapentine
- Efavirenz
- Dosing
- Isoniazid
- Medicine
- Regimen
- Pharmacokinetics
- Concomitant
- NONMEM
- Population
- Pharmacology
- Rifamycin
- Internal medicine